Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results
In This Article:
Q3 2024 marks highest ever in-market quarterly sales performance and fourth consecutive quarter of strong sales performance
LUND, Sweden, Oct. 17, 2024 /PRNewswire/ -- Hansa Biopharma today announced its interim report for January-September and third quarter 2024 financial results.
S?ren Tulstrup, President and CEO, Hansa Biopharma said, "The third quarter of 2024 marks the highest ever IDEFIRIX? sales performance to date, resulting in four consecutive quarters of strong sales performance. The launch of IDEFIRIX in Europe continues to advance with adoption in international organ allocation systems and an increase in new and repeat utilization in leading transplant clinics. Equally, we see strong momentum in our clinical development programs in autoimmune, gene therapy and transplantation. Enrollment in the Phase 3 GOOD-IDES-02 study in anti-GBM has reached 86%. In the Post Authorization Efficacy and Safety (PAES) study in kidney transplant enrolment has reached 78%. Finally, just after quarter end, we communicated positive results from the 12-month analysis of NICE-01, demonstrating that HNSA-5487 can robustly and very rapidly reduce IgG levels, has clear redosing potential, and a favorable safety and tolerability profile. Initial clinical development will focus on neuromyelitis optica (NMO), myelin oligodendrocyte glycoprotein antibody disease (MOGAD), and myasthenia gravis (MG)."
Financial Performance
The Company recorded total revenue of 78.4 MSEK. Of this, 69.5 MSEK is attributed to IDEFIRIX sales, marking the highest ever quarterly in-market sales. This excludes the impact of a 29.7 MSEK provision related to potential price adjustments from cumulative sales since the launch of IDEFIRIX in Europe in 2020. Of the total provision only 4.9 MSEK was related to Q3 sales. Net of the provision, Q3 2024 IDEFIRIX sales were 39.8 MSEK and total year to date IDEFIRIX sales were 114.5 MSEK. Previously, the Company recorded a provision of 19.9 MSEK in Q2 2024. Of this, 2.0 MSEK was related to sales in Q2 2024. Of the total provision taken in Q2 and Q3 2024, 42.7 MSEK relates to previous periods since launch in 2020.
Pipeline Progress
Progress across the pipeline included the strong momentum in enrollment in the Phase 3 GOOD-IDES-02 study in anti-GBM (86%), and in the Post Authorization Efficacy and Safety (PAES) study in kidney transplantation (78%). Further efficacy data from the 15-HMedIdes-09 Phase 2 trial in Guillain-Barré Syndrome (GBS) is scheduled to read out by the end of 2024. The ConfIdeS trial continues to progress following completed randomization in May and data from the study is expected to provide the basis for a Biologics License Application (BLA) with the US Food and Drug Administration (FDA) in the second half of 2025. On 7 October 2024, Hansa announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, assessing IgG recovery, immunogenicity and redosing potential.
Financial Summary
| MSEK, unless otherwise stated – unaudited | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 | |
| Total Revenue | 78.4 | 22.8 | 188.6 | 83.7 | |
| Provision1 | (29.7) | - | (49.6) | - | |
| Net revenue after provision | 48.7 | 22.8 | 139.0 | 83.7 | |
| SG&A expenses | (75.8) | (111.7) | (255.3) | (344.5) | |
| R&D expenses | (79.6) | (95.6) | (274.3) | (303.1) | |
| Loss from operations | (116.9) | (202.2) | (463.7) | (613.0) | |
| Loss for the period | (103.8) | (250.7) | (530.3) | (707.3) | |
| Net cash used in operations | (148.8) | (193.8) | (527.1) | (582.7) | |
| Cash and short-term investments | 553.5 | 908.2 | 553.5 | 908.2 | |
| EPS before and after dilution (SEK) | (1.53) | (4.78) | (8.67) | (13.49) | |
| Number of outstanding shares | 67,814,241 | 52,671,796 | 67,814,241 | 52,671,796 | |
| Weighted average number of shares before and after dilution | 67,814,241 | 52,597,502 | 61,162,934 | 52,495,705 | |
| No of employees at the end of the period | 135 | 168 | 135 | 168 | |
| 1 Product sales in the third quarter 2024 totaled 69.5 MSEK. Sales were offset by a provision totaling 29.7 MSEK for potential credits associated with volume discounts and rebates. Year to date 2024 IDEFIRIX product sales totaled 164.1 MSEK and were offset by a provision totaling 49.6 MSEK. Net of the provision, year-to-date 2024 product sales totaled 114.5 MSEK. | | ||||
| | | | | | |
Conference Call Details
Hansa Biopharma will host a telephone conference today Thursday, October 17, 2024, at 14:00 CET / 8:00 am ET.
The event will be hosted by S?ren Tulstrup, President and CEO, Evan Ballantyne, CFO, and Hitto Kaufmann, CR&DO. The call will include a review of the interim results and a business and pipeline update. It will be held in English.
Slides used in the presentation will be live on the company website during the call under Events & Presentations and will also be made available online after the call.
To participate in the telephone conference, please use the dial-in details provided below:
Participant Dial In (Toll Free): 1-877-270-2148
Participant International Dial In: 1-412-902-6510
*Please ask to be joined into the Hansa Biopharma call
Join the webcast here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ld2DsRXz
For the full financial calendar and list of events in 2024 please visit https://www.hansabiopharma.com/investors/calendar/
This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act.
For more information:
Evan Ballantyne, Chief Financial Officer
[email protected]
Stephanie Kenney, VP Global Corporate Affairs
[email protected]
Notes to editors
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa Biopharma has a rich and expanding research and development program based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.
?2024 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.
This information was brought to you by Cision https://news.cision.com
The following files are available for download:
| 20241017-HNSA-Q3-2024-Quarterly-Report-ENG |
View original content:https://www.prnewswire.co.uk/news-releases/hansa-biopharma-reports-third-quarter-and-interim-january---september-2024-financial-results-302278809.html